BAC
Bank of America Corporation
BAC has the edge over CRWV overall, supported by lower modeled downside and stronger fundamentals.
CRWV
CoreWeave, Inc. Class A Common Stock
CRWV's outlook is improving, though it still trails on the overall score.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
CRWV Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Strong |
CRWV's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
CRWV PE Valuation
CRWV has no meaningful PE right now: it lost money over the past year.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
CRWV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Low |
Analysts expect CRWV's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over CRWV on earnings quality, reporting a profit while its opponent remains loss making.
CRWV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.31 | -$1.83 |
| Q2 2026 | -$3.26 | -$0.16 |
| Q1 2026 | -$2.72 | +$0.62 |
| Q4 2025 | -$2.81 | -$0.64 |
| Q3 2025 | -$2.48 | -$0.06 |
CRWV lost $4.31 per share over the past year, a bigger loss than the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over CRWV on profitability, with a higher operating margin.
CRWV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +168% |
| Q2 2026 | $2.6B | +112% |
| Q1 2026 | $2.1B | +112% |
| Q4 2025 | $1.6B | +110% |
| Q3 2025 | $1.4B | +134% |
| Q2 2025 | $1.2B | +207% |
| Q1 2025 | $981.6M | +420% |
| Q4 2024 | $747.4M | +544% |
CRWV has the edge over BAC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.7% | +1.9 points |
| Q2 2026 | -1.9% | -3.5 points |
| Q1 2026 | -6.9% | -4.1 points |
| Q4 2025 | -5.7% | -21 points |
| Q3 2025 | 3.8% | -16 points |
| Q2 2025 | 1.6% | -18 points |
| Q1 2025 | -2.8% | -12 points |
| Q4 2024 | 15% | +17 points |
CRWV's operating margin was 5.7% last quarter, up 1.9 points from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC has the edge over CRWV on cash generation, producing positive trailing cash flow while its opponent burns cash.
CRWV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.5B | -$6.8B |
| Q2 2026 | -$5.7B | -$3B |
| Q1 2026 | -$4.7B | -$3.4B |
| Q4 2025 | -$2.5B | +$810.3M |
| Q3 2025 | -$699.8M | -$125.8M |
| Q2 2025 | -$2.7B | -$339.3M |
| Q1 2025 | -$1.3B | -553% |
| Q4 2024 | -$3.3B | -$2.2B |
CRWV has burned cash in almost every quarter: −$20.4B over the past year, against −$8.1B the year before.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over CRWV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
CRWV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +8M shares |
| 1 year | +12% | +61.1M shares |
CRWV has 559M diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | $1.5M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | $32.1M |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
CRWV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.8x | Net Cash |
| Q2 2026 | -1.5x | Net Cash |
| Q1 2026 | 7.6x | High |
| Q4 2025 | 7.6x | High |
| Q3 2025 | 5.6x | High |
| Q2 2025 | 6.5x | High |
| Q1 2025 | 8.4x | High |
| Q4 2024 | 19.3x | High |
CRWV has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
CRWV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.7 | Neutral |
| Stochastic | 11.3 | Oversold |
CRWV's weekly RSI is 40 (neutral) and its Stochastic is 11 (oversold).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
CRWV PE vs Technology Sector
CRWV has no meaningful PE right now: it lost money over the past year.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has stronger trend alignment. BAC is above 1 of 5 weekly averages versus CRWV above 0 of 3.
CRWV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $66.6 | 15% below |
| 20 week MA | $77.4 | 27% below |
| 50 week MA | $87.4 | 35% below |
CRWV is in a downtrend: it's below all three of its weekly moving averages, and 35% below its 50-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has the edge over CRWV on returns for 2026, with the stronger performance.
CRWV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $40.0 | $76.4 | +91% |
| 2026 YTD | $76.4 | $56.6 | -26% |
CRWV has finished every year since 2025 higher, and it's down 26% so far in 2026.